Chemokine receptor CCR5: From AIDS to atherosclerosis

British Journal of Pharmacology

Volumn 162, Issue 7, 2011, Pages 1453-1469

  Jones, K L ^a   Maguire, J J ^a   Davenport, A P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

atherosclerosis; cardiovascular disease; CCL3 (MIP 1 ); CCL4 (MIP 1 ); CCL5 (RANTES); CCR5; CCR5delta32; chemokine receptor; G protein coupled receptor; HIV

Indexed keywords

CHEMOKINE RECEPTOR CCR5; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; RANTES;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CODON; CORONARY ARTERY BYPASS GRAFT; GENE DELETION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; VEIN GRAFT DISEASE; VIRUS ENTRY; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ATHEROSCLEROSIS; CHEMOKINES; HUMANS; RECEPTORS, CCR5;

EID: 79952385006     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01147.x     Document Type: Review

References (167)

1. Afzal AR, Kiechl S, Daryani YP, Weerasinghe A, Zhang Y, Reindl M, et al. (2008). Common CCR5-del32 frameshift mutation associated with serum levels of inflammatory markers and cardiovascular disease risk in the Bruneck population. Stroke 39: 1972-1978.
2. Alexander S, Mathie A, Peters J, (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158: S1-S254.
3. Ali ZA, Bursill CA, Hu Y, Choudhury RP, Xu Q, Greaves DR, et al. (2005). Gene transfer of a broad spectrum CC-chemokine inhibitor reduces vein graft atherosclerosis in apolipoprotein E-knockout mice. Circulation 112: I-235-I-241.
4. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, et al. (1996). CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272: 1955-1958. (Pubitemid 26234510)
5. Andjelkovic AV, Pachter JS, (2000). Characterization of binding sites for chemokines MCP-1 and MIP-1alpha on human brain microvessels. J Neurochem 75: 1898-1906.
6. Apostolakis S, Baritaki S, Kochiadakis GE, Igoumenidis NE, Panutsopulos D, Spandidos DA, (2007). Effects of polymorphisms in chemokine ligands and receptors on susceptibility to coronary artery disease. Thromb Res 119: 63-71. (Pubitemid 44724920)
7. Ardigo D, Assimes TL, Fortmann SP, Go AS, Hlatky M, Hytopoulos E, et al. for the ADVANCE Investigators (2007). Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease. Physiol Genomics 31: 402-409. (Pubitemid 350127780)
8. Aukrust P, Ueland T, Muller F, Andreassen AK, Nordoy I, Aas H, et al. (1998). Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 97: 1136-1143. (Pubitemid 28152886)
9. Aukrust P, Yndestad A, Smith C, Ueland T, Gullestad L, Damas JK, (2007). Chemokines in cardiovascular risk prediction. Thromb Haemost 97: 748-754. (Pubitemid 46779960)
10. Aukrust P, Halvorsen B, Yndestad A, Ueland T, Oie E, Otterdal K, et al. (2008). Chemokines and cardiovascular risk. Arterioscler Thromb Vasc Biol 28: 1909-1919.
11. Balistreri CR, Candore G, Caruso M, Incalcaterra E, Franceschi C, Caruso C, (2008). Role of polymorphisms of CC-chemokine receptor-5 gene in acute myocardial infarction and biological implications for longevity. Haematologica 93: 637-638. (Pubitemid 351536399)
12. Berger O, Gan X, Gujuluva C, Burns AR, Sulur G, Stins M, et al. (1999). CXC and CC chemokine receptors on coronary and brain endothelia. Mol Med 5: 795-805. (Pubitemid 32937038)
13. Blain KY, Kwiatkowski W, Zhao Q, LaFleur D, Naik C, Chun T-W, et al. (2007). Structural and functional characterization of CC chemokine CCL14. Biochemistry 46: 10008-10015. (Pubitemid 47378591)
14. Blanpain C, Migeotte I, Lee B, Vakili J, Doranz BJ, Govaerts C, et al. (1999). CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood 94: 1899-1905. (Pubitemid 29430405)
15. Boccara F, (2008). Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors. AIDS 22: S19-S26.
16. Boger CA, Fischereder M, Deinzer M, Aslanidis C, Schmitz G, Stubanus M, et al. (2005). RANTES gene polymorphisms predict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients. Atherosclerosis 183: 121-129. (Pubitemid 41416830)
17. Braunersreuther V, Zernecke A, Arnaud C, Liehn EA, Steffens S, Shagdarsuren E, et al. (2007). Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol 27: 373-379. (Pubitemid 46143054)
18. Braunersreuther V, Steffens S, Arnaud C, Pelli G, Burger F, Proudfoot A, et al. (2008). A Novel RANTES Antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler Thromb Vasc Biol 28: 1090-1096.
19. Breland UM, Michelsen AE, Skjelland M, Folkersen L, Krohg-Sorensen K, Russell D, et al. (2010). Raised MCP-4 levels in symptomatic carotid atherosclerosis-an inflammatory link between platelet and monocyte activation. Cardiovasc Res 86: 265-273.
20. Briones MA, Phillips DJ, Renshaw MA, Hooper WC, (2001). Expression of chemokine by human coronary-artery and umbilical-vein endothelial cells and its regulation by inflammatory cytokines. Coron Artery Dis 12: 179-186. (Pubitemid 32402349)
21. Budzyn K, Lob HE, McCann LA, Goronzy JJ, Weyand CM, Proudfoot AE, et al. (2008). Importance of CCR5 in the development of angiotensin II-induced hypertension and vascular dysfunction. Hypertension 52: E108. Abstract P268.
22. Burns WR, Wang Y, Tang PC, Ranjbaran H, Iakimov A, Kim J, et al. (2005). Recruitment of CXCR3+ and CCR5+ T cells and production of interferon-gamma- inducible chemokines in rejecting human arteries. Am J Transplant 5: 1226-1236. (Pubitemid 40839410)
23. Bursill CA, Choudhury RP, Ali Z, Greaves DR, Channon KM, (2004). Broad-spectrum CC-chemokine blockade by gene transfer inhibits macrophage recruitment and atherosclerotic plaque formation in apolipoprotein E-knockout mice. Circulation 110: 2460-2466. (Pubitemid 39407354)
24. Bursill CA, McNeill E, Wang L, Hibbitt OC, Wade-Martins R, Paterson DJ, et al. (2009). Lentiviral gene transfer to reduce atherosclerosis progression by long-term CC-chemokine inhibition. Gene Ther 16: 93-102.
25. Bursill CA, Castro ML, Beattie DT, Nakhla S, van der Vorst E, Heather AK, et al. (2010). High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo. Arterioscler Thromb Vasc Biol 27: 929-935.
26. Castellheim A, Hoel TN, Videm V, Fosse E, Pharo A, Svennevig JL, et al. (2008). Biomarker profile in off-pump and on-pump coronary artery bypass grafting surgery in low-risk patients. Ann Thorac Surg 85: 1994-2002. (Pubitemid 351695495)
27. Castor MG, Rezende B, Resende CB, Alessandri AL, Fagundes CT, Sousa LP, et al. (2010). The CCL3/macrophage inflammatory protein-1alpha-binding protein evasin-1 protects from graft-versus-host disease but does not modify graft-versus-leukemia in mice. J Immunol 184: 2646-2654.
28. Cavusoglu E, Eng C, Chopra V, Clark LT, Pinsky DJ, Marmur JD, (2007). Low plasma RANTES levels are an independent predictor of cardiac mortality in patients referred for coronary angiography. Arterioscler Thromb Vasc Biol 27: 929-935. (Pubitemid 46606727)
29. Charo IF, Hills R, Horuk R, Matsushima K, Murphy PM, Oppenheim JJ, (2009). Chemokine receptors: CCR5. Last modified on 2010-06-29. Accessed on 2010-08-13. IUPHAR database (IUPHAR-DB). Available at
30. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, et al. (1996). The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85: 1135-1148. (Pubitemid 26231178)
31. Chou C-C, Fine JS, Pugliese-Sivo C, Gonsiorek W, Davies L, Deno G, et al. (2002). Pharmacological characterization of the chemokine receptor, hCCR1 in a stable transfectant and differentiated HL-60 cells: antagonism of hCCR1 activation by MIP-1beta. Br J Pharmacol 137: 663-675. (Pubitemid 35333092)
32. Clementi M, Lazzarin A, (2010). Human immunodeficiency virus type 1 fitness and tropism: concept, quantification, and clinical relevance. Clin Microbiol Infect 16: 1532-1538.
33. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P, (1995). Identification of RANTES, MIP-1alpha, and MIP-1beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270: 1811-1815.
34. Cohn SK Jr, Weaver LT, (2006). The Black Death and AIDS: CCR5-Delta32 in genetics and history. QJM 99: 497-503. (Pubitemid 44304834)
35. Colonnello JS, Hance KA, Shames ML, Wyble CW, Ziporin SJ, Leidenfrost JE, et al. (2003). Transient exposure to elastase induces mouse aortic wall smooth muscle cell production of MCP-1 and RANTES during development of experimental aortic aneurysm. J Vasc Surg 38: 138-146. (Pubitemid 41123301)
36. Combadiere C, Ahuja SK, Tiffany HL, Murphy PM, (1996). Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1alpha, MIP-1beta, and RANTES. J Leukoc Biol 60: 147-152. (Pubitemid 26248894)
37. 3CR1, and CCR5 abrogates Ly6Chi and Ly6Clo monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 117: 1649-1657. (Pubitemid 351482605)
38. Correia LC, Andrade BB, Borges V, Clarêncio J, Bittencourt AP, Freitas R, et al. (2010). Prognostic value of cytokines and chemokines in addition to the GRACE score in non-ST-elevation acute coronary syndromes. Clin Chim Acta 411: 540-545.
39. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. (1996). Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273: 1856-1862.
40. DeJesus E, Walmsley S, Cohen C, Cooper D, Hirschel B, Goodrich J, et al. (2008). Fasted lipid changes after administration of maraviroc or efavirenz in combination with zidovudine and lamivudine for 48 weeks to treatment-naïve HIV-infected patients. 15th Conference on Retroviruses and Opportunistic Infections. Available at
41. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. (1996). Identification of a major co-receptor for primary isolates of HIV-1. Nature 381: 661-666. (Pubitemid 26197679)
42. DiPalma S, Frohlich JJ, Hill JS, (2008). RANTES levels predict angiographic coronary artery disease but not mortality in an angiography population. Arterioscler Thromb Vasc Biol 28: e32-e149. P489.
43. 1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 38: 395-405. (Pubitemid 32769559)
44. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, et al. (1996). A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85: 1149-1158. (Pubitemid 26235280)
45. Dorfmüller P, Zarka V, Durand-Gasselin I, Monti G, Balabanian K, Garcia G, et al. (2002). Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med 165: 534-539. (Pubitemid 34165478)
46. Dorr P, Perros M, (2008). CCR5 inhibitors in HIV-1 therapy. Expert Opin Drug Discov 3: 1345-1361.
47. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, et al. (2005). Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49: 4721-4732. (Pubitemid 41552605)
48. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. (1996). HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381: 667-673. (Pubitemid 26197680)
49. Eagle KA, Guyton RA, Davidoff R, Ewy GA, Fonger J, Gardner TJ, et al. (1999). ACC/AHA guidelines for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association task force on Practice Guidelines (Committee to revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). J Am Coll Cardiol 34: 1262-1347. (Pubitemid 29500568)
50. Eefting D, Bot I, de Vries MR, Schepers A, van Bockel JH, Van Berkel TJ, et al. (2009). Local lentiviral short hairpin RNA silencing of CCR2 inhibits vein graft thickening in hypercholesterolemic apolipoprotein E3-Leiden mice. J Vasc Surg 50: 152-160.
51. Ezerzer C, Harris N, (2007). Physiological immunity or pathological autoimmunity-a question of balance. Autoimmun Rev 6: 488-496. (Pubitemid 47082428)
52. Faure E, (2008). Could FIV zoonosis responsible of the breakdown of the pathocenosis which has reduced the European CCR5-Delta32 allele frequencies. Virol J 5: 119.
53. Faure E, Royer-Carenzi M, (2008). Is the European spatial distribution of the HIV-1-resistant CCR5-Delta32 allele formed by a breakdown of the pathocenosis due to the historical Roman expansion? Infect Genet Evol 8: 864-874.
54. FDA (2009). Expanded indication for Selzentry (maraviroc) [internet]. Available at [accessed 4 May 2010].
55. Gautier EL, Jakubzick C, Randolph GJ, (2009). Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. Arterioscler Thromb Vasc Biol 29: 1412-1418.
56. Ghilardi G, Biondi ML, Turri O, Pateri F, d'Eril GM, Scorza R, (2008). Genetic control of chemokines in severe human internal carotid artery stenosis. Cytokine 41: 24-28. (Pubitemid 350309714)
57. Gleissner CA, von Hundelshausen P, Ley K, (2008). Platelet chemokines in vascular disease. Arterioscler Thromb Vasc Biol 28: 1920-1927.
58. Gonzalez P, Alvarez R, Batalla A, Reguero JR, Alvarez V, Astudillo A, et al. (2001). Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun 2: 191-195. (Pubitemid 33676982)
59. Gurbel PA, Kreutz RP, Bliden KP, DiChiara J, Tantry US, (2008). Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression. Am Heart J 155: 56-61. (Pubitemid 350234773)
60. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. (2007). Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 204: 2449-2460. (Pubitemid 47529329)
61. Hayes IM, Jordan NJ, Towers S, Smith G, Paterson JR, Earnshaw JJ, et al. (1998). Human vascular smooth muscle cells express receptors for CC chemokines. Arterioscler Thromb Vasc Biol 18: 397-403. (Pubitemid 28125634)
62. Hedrick PW, Verrelli BC, (2006). 'Ground truth' for selection on CCR5-Delta 32. Trends Genet 22: 293-296.
63. Horiguchi K, Kitagawa-Sakakida S, Sawa Y, Li ZZ, Fukushima N, Shirakura R, et al. (2002). Selective chemokine and receptor gene expressions in allografts that develop transplant vasculopathy. J Heart Lung Transplant 21: 1090-1100. (Pubitemid 35190326)
64. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, et al. (1996). The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 2: 1240-1243. (Pubitemid 26375409)
65. Hummel S, Schmidt D, Kremeyer B, Herrmann B, Oppermann M, (2005). Detection of the CCR5-Delta32 HIV resistance gene in Bronze Age skeletons. Genes Immun 6: 371-374. (Pubitemid 40903412)
66. von Hundelshausen P, Weber KS, Huo Y, Proudfoot AE, Nelson PJ, Ley K, et al. (2001). RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 103: 1772-1777. (Pubitemid 32291415)
67. von Hundelshausen P, Koenen RR, Sack M, Mause SF, Adriaens W, Proudfoot AE, et al. (2005). Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 105: 924-930. (Pubitemid 40170856)
68. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, et al. (2003). Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 9: 61-67. (Pubitemid 36098261)
69. Hyde CL, MacInnes A, Sanders FA, Thompson JF, Mazzarella RA, Faergeman O, et al. (2010). Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients. Circ Cardiovasc Genet 3: 162-168.
70. Ingersoll MA, Spanbroek R, Lottaz C, Gautier EL, Frankenberger M, Hoffmann R, et al. (2010). Comparison of gene expression profiles between human and mouse monocyte subsets. Blood 115: e10-e19.
71. Jabs A, Okamoto E-I, Vinten-Johansen J, Bauriedel G, Wilcox JN, (2007). Sequential patterns of chemokine- and chemokine receptor-synthesis following vessel wall injury in porcine coronary arteries. Atherosclerosis 192: 75-84. (Pubitemid 46602307)
72. de Jager SC, Kraaijeveld AO, Grauss RW, de Jager W, Liem S-S, van der Hoeven BL, et al. (2008). CCL3 (MIP-1alpha) levels are elevated during acute coronary syndromes and show strong prognostic power for future ischemic events. J Mol Cell Cardiol 45: 446-452.
73. Jang Y, Chae JS, Hyun YJ, Koh SJ, Kim JY, Ko MJ, et al. (2007). The RANTES -403G>A promoter polymorphism in Korean men: association with serum RANTES and coronary artery disease. Clin Sci (Lond) 113: 349-356. (Pubitemid 47572275)
74. Jones K, Kuc R, Katugampola S, Davenport A, (2007). Expression of the chemokines RANTES and MIP-1β in human vasculature and atherosclerotic plaque. Proceedings of the British Pharmacological Society. Available at
75. Jones KL, Kuc RE, Katugampola SD, Davenport AP, (2008). Detection of MIP-1beta, MIP-1alpha and RANTES, endogenous ligands of chemokine receptor CCR5, in normal and atherosclerotic human vasculature. Fundam Clin Pharmacol 22: 71-72.
76. Jones K, Maguire J, Katugampola S, Davenport A, (2009). Blockade of the Human Immunodeficiency Virus (HIV)-1 co-receptor CCR5 with novel antagonists reduces neointimal development in a model of human saphenous vein graft disease. Proceedings of the British Pharmacological Society. Available at
77. Jordan NJ, Watson ML, Williams RJ, Roach AG, Yoshimura T, Westwick J, (1997). Chemokine production by human vascular smooth muscle cells: modulation by IL-13. Br J Pharmacol 122: 749-757. (Pubitemid 27453102)
78. Kanmogne GD, Grammas P, Kennedy RC, (2000). Analysis of human endothelial cells and cortical neurons for susceptibility to HIV-1 infection and co-receptor expression. J Neurovirol 6: 519-528. (Pubitemid 32098066)
79. Kanmogne GD, Kennedy RC, Grammas P, (2001). Analysis of human lung endothelial cells for susceptibility to HIV type 1 infection, coreceptor expression, and cytotoxicity of gp120 protein. AIDS Res Hum Retroviruses 17: 45-53. (Pubitemid 32098007)
80. Karshovska E, Schober A, (2008). Mechanisms of arterial remodeling and neointima formation: an updated view on the chemokine system. Drug Discov Today Dis Mech 5: e293-e298.
81. Kim S, Iwao H, (2000). Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52: 11-34. (Pubitemid 30127593)
82. Kobusiak-Prokopowicz M, Orzeszko J, Mazur G, Mysiak A, Orda A, Mazurek W, (2005). Kinetics of chemokines in acute myocardial infarction. Kardiol Pol 62: 301-314.
83. Kobusiak-Prokopowicz M, Orzeszko J, Mazur G, Mysiak A, Orda A, Poreba R, et al. (2007). Chemokines and left ventricular function in patients with acute myocardial infarction. Eur J Intern Med 18: 288-294. (Pubitemid 46898778)
84. Koenen RR, Weber C, (2010). Therapeutic targeting of chemokine interactions in atherosclerosis. Nat Rev Drug Discov 9: 141-153.
85. Koenen RR, von Hundelshausen P, Nesmelova IV, Zernecke A, Liehn EA, Sarabi A, et al. (2009). Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med 15: 97-103.
86. Kovacic JC, Gupta R, Lee AC, Ma M, Fang F, Tolbert CN, et al. (2010). Stat3-dependent acute Rantes production in vascular smooth muscle cells modulates inflammation following arterial injury in mice. J Clin Invest 120: 303-314.
87. Kraaijeveld AO, de Jager SC, de Jager WJ, Prakken BJ, McColl SR, Haspels I, et al. (2007). CC Chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms. Circulation 116: 1931-1941. (Pubitemid 350287089)
88. Krohn R, Raffetseder U, Bot I, Zernecke A, Shagdarsuren E, Liehn EA, et al. (2007). Y-Box binding protein-1 controls cc chemokine ligand-5 (CCL5) expression in smooth muscle cells and contributes to neointima formation in atherosclerosis-prone mice. Circulation 116: 1812-1820. (Pubitemid 350287106)
89. Kuziel WA, Dawson TC, Quinones M, Garavito E, Chenaux G, Ahuja SS, et al. (2003). CCR5 deficiency is not protective in the early stages of atherogenesis in apoE knockout mice. Atherosclerosis 167: 25-32. (Pubitemid 36255632)
90. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. (1996). Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86: 367-377. (Pubitemid 26272077)
91. Luckow B, Joergensen J, Chilla S, Li J-P, Henger A, Kiss E, et al. (2004). Reduced intragraft mRNA expression of matrix metalloproteinases Mmp3, Mmp12, Mmp13 and Adam8, and diminished transplant arteriosclerosis in Ccr5-deficient mice. Eur J Immunol 34: 2568-2578. (Pubitemid 39302814)
92. Lukacs NW, Kunkel SL, Allen R, Evanoff HL, Shaklee CL, Sherman JS, et al. (1995). Stimulus and cell-specific expression of C-X-C and C-C chemokines by pulmonary stromal cell populations. Am J Physiol Lung Cell Mol Physiol 268: L856-L861.
93. deLuna A, (2008). Mouse models in atherosclerosis. Drug Discov Today Dis Models 5: 157-163.
94. Lutgens E, Faber B, Schapira K, Evelo CT, van Haaften R, Heeneman S, et al. (2005). Gene profiling in atherosclerosis reveals a key role for small inducible cytokines: validation using a novel monocyte chemoattractant protein monoclonal antibody. Circulation 111: 3443-3452. (Pubitemid 40923398)
95. Maguire J, Katugampola S, Mansfield R, Napier C, Davenport A, (2008). Novel vasoconstrictor action of the inflammatory chemokine MIP-1 beta in human vasculature in vitro: antagonism by the HIV/AIDS drug maraviroc. Fundam Clin Pharmacol 22: 54.
96. Magyar MT, Bereczki D, Csipo I, Gyimesi E, Csiba L, Valikovics A, et al. (2007). Elevated white blood cell count, CRP and fibrinogen levels are not associated with increased anti-endothelial and anti-ox-LDL antibody, MCP-1, and RANTES levels in early onset occlusive carotid artery disease. Cytokine 37: 44-50. (Pubitemid 46575286)
97. -/- mice. Cardiovasc Drugs Ther 23: 113-120.
98. Marfaing-Koka A, Devergne O, Gorgone G, Portier A, Schall T, Galanaud P, et al. (1995). Regulation of the production of the RANTES chemokine by endothelial cells. Synergistic induction by IFN-gamma plus TNF-alpha and inhibition by IL-4 and IL-13. J Immunol 154: 1870-1878.
99. 1 angiotensin II receptor antagonist irbesartan. J Cardiovasc Pharmacol 43: 191-199. (Pubitemid 38129676)
100. Mateo T, Nabah YN, Taha MA, Mata M, Cerda-Nicolas M, Proudfoot AE, et al. (2006). Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines. J Immunol 176: 5577-5586.
101. Mateo T, Nabah YN, Losada M, Estelles R, Company C, Bedrina B, et al. (2007). A critical role for TNFalpha in the selective attachment of mononuclear leukocytes to angiotensin-II-stimulated arterioles. Blood 110: 1895-1902. (Pubitemid 47443902)
102. Mause SF, von Hundelshausen P, Zernecke A, Koenen RR, Weber C, (2005). Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol 25: 1512-1518. (Pubitemid 40923377)
103. Motwani JG, Topol EJ, (1998). Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 97: 916-931. (Pubitemid 28113931)
104. Murray EJ, Leaman DP, Pawa N, Perkins H, Pickford C, Perros M, et al. (2010). A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41. J Virol 84: 7288-7299.
105. Napier C, Sale H, Mosley M, Rickett G, Dorr P, Mansfield R, et al. (2005). Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharmacol 71: 163-172. (Pubitemid 41713538)
106. Nibbs RJ, Yang J, Landau NR, Mao J-H, Graham GJ, (1999). LD78beta, A non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity. J Biol Chem 274: 17478-17483.
107. Nomura S, Uehata S, Saito S, Osumi K, Ozeki Y, Kimura Y, (2003). Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome. Thromb Haemost 89: 506-512. (Pubitemid 36329242)
108. Novembre J, Galvani AP, Slatkin M, (2005). The geographic spread of the CCR5 Delta32 HIV-resistance allele. PLoS Biol 3: e339.
109. Pai JK, Kraft P, Cannuscio CC, Manson JE, Rexrode KM, Albert CM, et al. (2006). Polymorphisms in the CC-chemokine receptor-2 (CCR2) and -5 (CCR5) genes and risk of coronary heart disease among US women. Atherosclerosis 186: 132-139.
110. Papaspyridonos M, Smith A, Burnand KG, Taylor P, Padayachee S, Suckling KE, et al. (2006). Novel candidate genes in unstable areas of human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 26: 1837-1844. (Pubitemid 44305338)
111. Parissis JT, Adamopoulos S, Venetsanou KF, Mentzikof DG, Karas SM, Kremastinos DT, (2002). Serum profiles of C-C chemokines in acute myocardial infarction: possible implication in postinfarction left ventricular remodeling. J Interferon Cytokine Res 22: 223-229. (Pubitemid 34275490)
112. Pattison JM, Nelson PJ, Huie P, Sibley RK, Krensky AM, (1996). RANTES chemokine expression in transplant-associated accelerated atherosclerosis. J Heart Lung Transplant 15: 1194-1199. (Pubitemid 26428394)
113. Petrkova J, Cermakova Z, Lukl J, Petrek M, (2005). CC chemokine receptor 5 (CCR5) deletion polymorphism does not protect Czech males against early myocardial infarction. J Intern Med 257: 564-566. (Pubitemid 40776518)
114. + T cells. J Virol 84: 6505-6514.
115. Potteaux S, Combadiere C, Esposito B, Casanova S, Merval R, Ardouin P, et al. (2005). Chemokine receptor CCR1 disruption in bone marrow cells enhances atherosclerotic lesion development and inflammation in mice. Mol Med 11: 16-20.
116. Potteaux S, Combadiere C, Esposito B, Lecureuil C, Ait-Oufella H, Merval R, et al. (2006). Role of bone marrow-derived CC-chemokine receptor 5 in the development of atherosclerosis of low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 26: 1858-1863. (Pubitemid 44305341)
117. Potteaux S, Ait-Oufella H, Mallat Z, (2008). Mouse models of atherosclerosis. Drug Discov Today Dis Models 4: 165-170. (Pubitemid 351944049)
118. Puhakka HL, Turunen P, Gruchala M, Bursill C, Heikura T, Vajanto I, et al. (2005). Effects of vaccinia virus anti-inflammatory protein 35K and TIMP-1 gene transfers on vein graft stenosis in rabbits. In Vivo 19: 515-521.
119. Quinones MP, Martinez HG, Jimenez F, Estrada CA, Dudley M, Willmon O, et al. (2007). CC chemokine receptor 5 influences late-stage atherosclerosis. Atherosclerosis 195: e92-e103. (Pubitemid 47561964)
120. Raport CJ, Gosling J, Schweickart VL, Gray PW, Charo IF, (1996). Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. J Biol Chem 271: 17161-17166. (Pubitemid 26244268)
121. Reape TJ, Groot PH, (1999). Chemokines and atherosclerosis. Atherosclerosis 147: 213-225. (Pubitemid 29512252)
122. del Rio Solá L, Aceves M, Dueñas AI, González-Fajardo JA, Vaquero C, Sanchez Crespo M, et al. (2009). Varicose veins show enhanced chemokine expression. Eur J Vasc Endovasc Surg 38: 635-641.
123. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL, et al. (2007). Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for high blood pressure research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 115: 2761-2788. (Pubitemid 46842793)
124. Ross R, (1999). Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126. (Pubitemid 29054847)
125. Rothenbacher D, Muller-Scholze S, Herder C, Koenig W, Kolb H, (2006). Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. Arterioscler Thromb Vasc Biol 26: 194-199. (Pubitemid 43732249)
126. Rottman J, Ganley K, Williams K, Wu L, Mackay C, Ringler D, (1997). Cellular localization of the chemokine receptor CCR5. Correlation to cellular targets of HIV-1 infection. Am J Pathol 151: 1341-1351. (Pubitemid 27479764)
127. Ruffing N, Sullivan N, Sharmeen L, Sodroski J, Wu L, (1998). CCR5 has an expanded ligand-binding repertoire and is the primary receptor used by MCP-2 on activated T cells. Cell Immunol 189: 160-168. (Pubitemid 28507257)
128. Safian RD, (2002). Accelerated atherosclerosis in saphenous vein bypass grafts: a spectrum of diffuse plaque instability. Prog Cardiovasc Dis 44: 437-448. (Pubitemid 34680191)
129. Saiura A, Sata M, Hiasa K-i, Kitamoto S, Washida M, Egashira K, et al. (2004). Antimonocyte chemoattractant protein-1 gene therapy attenuates graft vasculopathy. Arterioscler Thromb Vasc Biol 24: 1886-1890. (Pubitemid 39350308)
130. Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M, (1996a). Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 35: 3362-3367. (Pubitemid 26092558)
131. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al. (1996b). Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382: 722-725.
132. Sarjeant JM, Rabinovitch M, (2002). Understanding and treating vein graft atherosclerosis. Cardiovasc Pathol 11: 263-271. (Pubitemid 35292242)
133. Schecter AD, Calderon TM, Berman AB, McManus CM, Fallon JT, Rossikhina M, et al. (2000). Human vascular smooth muscle cells possess functional CCR5. J Biol Chem 275: 5466-5471. (Pubitemid 30115180)
134. Schepers A, Eefting D, Bonta PI, Grimbergen JM, de Vries MR, van Weel V, et al. (2006). Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. Arterioscler Thromb Vasc Biol 26: 2063-2069. (Pubitemid 44253789)
135. Schober A, Manka D, von Hundelshausen P, Huo Y, Hanrath P, Sarembock IJ, et al. (2002). Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 106: 1523-1529.
136. Sharda S, Gilmour A, Harris V, Singh VP, Sinha N, Tewari S, et al. (2008). Chemokine receptor 5 (CCR5) deletion polymorphism in North Indian patients with coronary artery disease. Int J Cardiol 124: 254-258. (Pubitemid 351173353)
137. Shukaliak JA, Dorovini-Zis K, (2000). Expression of the beta-chemokines RANTES and MIP-1 beta by human brain microvessel endothelial cells in primary culture. J Neuropathol Exp Neurol 59: 339-352. (Pubitemid 30257563)
138. Simeoni E, Winkelmann BR, Hoffmann MM, Fleury S, Ruiz J, Kappenberger L, et al. (2004). Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur Heart J 25: 1438-1446. (Pubitemid 39078251)
139. Stephens JC, Reich DE, Goldstein DB, Shin HD, Smith MW, Carrington M, et al. (1998). Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet 62: 1507-1515. (Pubitemid 28307122)
140. Surmi BK, Hasty AH, (2010). The role of chemokines in recruitment of immune cells to the artery wall and adipose tissue. Vascul Pharmacol 52: 27-36.
141. Szalai C, Duba J, Prohaszka Z, Kalina A, Szabo T, Nagy B, et al. (2001). Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis 158: 233-239. (Pubitemid 32735489)
142. 3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 117: 185-194. (Pubitemid 46048465)
143. Tatewaki H, Egashira K, Kimura S, Nishida T, Morita S, Tominaga R, (2007). Blockade of monocyte chemoattractant protein-1 by adenoviral gene transfer inhibits experimental vein graft neointimal formation. J Vasc Surg 45: 1236-1243. (Pubitemid 46817835)
144. Telenti A, (2009). Safety concerns about CCR5 as an antiviral target. Curr Opin HIV AIDS 4: 131-135.
145. Tereshchenko I, Petrkova J, Mrazek F, Navratilova Z, Lukl J, Voevoda M, et al. (2008). Chemokine RANTES -403 G/A polymorphism in two Slavonic populations with myocardial infarction. Tissue Antigens 71: 333-334. Abstract P127.
146. Tripathy D, Thirumangalakudi L, Grammas P, (2007). Expression of macrophage inflammatory protein 1-alpha is elevated in Alzheimer's vessels and is regulated by oxidative stress. J Alzheimers Dis 11: 447-455. (Pubitemid 47094015)
147. Tripathy D, Thirumangalakudi L, Grammas P, (2010). RANTES upregulation in the Alzheimer's disease brain: a possible neuroprotective role. Neurobiol Aging 31: 8-16.
148. Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, et al. (2002). HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 99: 395-400. (Pubitemid 34060372)
149. Veillard NR, Kwak B, Pelli G, Mulhaupt F, James RW, Proudfoot AE, et al. (2004). Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 94: 253-261. (Pubitemid 38197459)
150. Victor M, Kimbiris D, Iskandrian A, Mintz G, Bemis C, Procacci P, et al. (1981). Spasm of a saphenous vein bypass graft. A possible mechanism for occlusion of the venous graft. Chest 80: 413-415. (Pubitemid 11020003)
151. Vogiatzi K, Voudris V, Apostolakis S, Kochiadakis GE, Thomopoulou S, Zaravinos A, et al. (2009). Genetic diversity of RANTES gene promoter and susceptibility to coronary artery disease and restenosis after percutaneous coronary intervention. Thromb Res 124: 84-89.
152. Waehre T, Damas JK, Gullestad L, Holm AM, Pedersen TR, Arnesen KE, et al. (2003). Hydroxymethylglutaryl coenzyme A reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol 41: 1460-1467. (Pubitemid 36543360)
153. van Wanrooij EJ, Happe H, Hauer AD, de Vos P, Imanishi T, Fujiwara H, et al. (2005). HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 25: 2642-2647. (Pubitemid 43732291)
154. Weber C, (2005). Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 96: 612-616. (Pubitemid 40478327)
155. Weber C, (2010). Obstacles and options in the quest for drug candidates against vascular disease. Thromb Haemost 104: 1-3.
156. Weber C, Zernecke A, Libby P, (2008). The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 8: 802-815.
157. Weissman D, Rabin RL, Arthos J, Rubbert A, Dybul M, Swofford R, et al. (1997). Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature 389: 981-985. (Pubitemid 27485691)
158. Wells TN, Power CA, Shaw JP, Proudfoot AE, (2006). Chemokine blockers-therapeutics in the making? Trends Pharmacol Sci 27: 41-47. (Pubitemid 43063123)
159. Westerweel PE, Rabelink TJ, Rookmaaker MB, Gröne H-J, Verhaar MC, (2008). RANTES is required for ischaemia-induced angiogenesis, which may hamper RANTES-targeted anti-atherosclerotic therapy. Thromb Haemost 99: 794-795. (Pubitemid 351694243)
160. Wilcox JN, Nelken NA, Coughlin SR, Gordon D, Schall TJ, (1994). Local expression of inflammatory cytokines in human atherosclerotic plaques. J Atheroscler Thromb 1: S10-S13.
161. Wu Y, Mukaida N, Liu T, Jia YQ, Zhu HL, Yang YM, et al. (2009). MMP-9 expression profile in inflammatory cells of Mip-1alpha knockout mice and Mip-1alpha receptor knockout mice. Sichuan Da Xue Xue Bao Yi Xue Ban 40: 374-377.
162. Zadelaar S, Kleemann R, Verschuren L, de Vries-Van der Weij J, van der Hoorn J, Princen HM, et al. (2007). Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 27: 1706-1721. (Pubitemid 47207165)
163. Zernecke A, Weber C, (2010). Chemokines in the vascular inflammatory response of atherosclerosis. Cardiovasc Res 86: 192-201.
164. Zernecke A, Liehn EA, Gao JL, Kuziel WA, Murphy PM, Weber C, (2006). Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. Blood 107: 4240-4243. (Pubitemid 43801346)
165. Zhang L-N, da Cunha V, Martin-McNulty B, Rutledge J, Vergona R, Sullivan ME, et al. (2007). Monocyte chemoattractant protein-1 or macrophage inflammatory protein-1alpha deficiency does not affect angiotensin II-induced intimal hyperplasia in carotid artery ligation model. Cardiovasc Pathol 16: 231-236. (Pubitemid 47048748)
166. Zimmerman PA, Buckler-White A, Alkhatib G, Spalding T, Kubofcik J, Combadiere C, et al. (1997). Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 3: 23-36. (Pubitemid 27142522)
167. Zlotnik A, Yoshie O, (2000). Chemokines: a new classification system and their role in immunity. Immunity 12: 121-127. (Pubitemid 30398626)